This is a ready-to-use matrix for allocating a limited pool of qualified person-in-plant staff across every concurrent CDMO campaign competing for coverage. It answers a different question than the single-campaign risk table in the person-in-plant oversight article: not whether one campaign needs a PIP, but which campaigns get one when there are more risk-flagged campaigns running at once than there are people to staff them. Replace every <<FILL: ...>> placeholder with your own specifics. A filled specimen follows.
Document control header
| Field | Entry |
|---|---|
| Document title | PIP Portfolio Coverage Prioritization Matrix, <<FILL: period, e.g. Q3 2026>> |
| Document number | <<FILL: e.g. PIP-PM-2026-Q3>> |
| Version | <<FILL>> |
| Effective date | <<FILL>> |
| Prepared by | <<FILL: e.g. PIP Program Lead>> |
| Reviewed by | <<FILL: Sponsor Quality Leadership>> |
1. Purpose
This matrix ranks every active or upcoming CDMO campaign that could plausibly need person-in-plant coverage during the period above, scores each against a common set of portfolio risk factors, and records the resulting coverage decision, its rationale, and its owner. Its job is to replace an availability-driven allocation, whoever asks first, or whoever a program manager happens to think of, with a documented, risk-ranked one, so a reviewer sees why a given campaign got the coverage level it got, not just that it did or didn’t.
2. Scope
| Dimension | Decision |
|---|---|
| Period covered | <<FILL: e.g. rolling 90 days, or a fixed quarter>> |
| Campaigns in scope | <<FILL: every campaign meeting the single-campaign risk criteria in the linked article, across all active CDMO relationships>> |
| Available PIP capacity this period | <<FILL: named individuals or FTE count, with qualification scope for each>> |
| Out of scope | <<FILL: e.g. campaigns already scored as routine, mature, clean-trend under the single-campaign risk table>> |
3. Scoring methodology
Score each campaign on the five factors below, 1 (lowest priority) to 5 (highest), and sum for a composite score. The scale is directional, not a precision instrument; its job is to force an explicit comparison across campaigns competing for the same limited capacity, not to produce a defensible number to two decimal places.
| Factor | 1 (low) | 3 (moderate) | 5 (high) |
|---|---|---|---|
| Campaign risk tier (per the single-campaign risk table) | Mature site, clean deviation trend | Complex or historically failure-prone unit operation | First campaign at a new site, open quality concern, or a non-recoverable batch |
| Batch value / patient impact if lost | Standard commercial batch, readily repeated | Elevated cost or schedule impact if lost | Autologous or otherwise non-recoverable batch; no second chance |
| Days until the next regulatory interaction tied to this site or product | No near-term interaction | A filing or comparability claim references this campaign within the next two quarters | A pre-approval inspection, for-cause inspection, or filed submission depends directly on this campaign’s outcome |
| Site relationship maturity | Long-standing, well-performing partner | Established relationship, moderate performance history | New relationship, fewer than three prior campaigns |
| PIP qualification match available | A qualified, unassigned PIP is available for this specific product and process | A PIP is available but needs incremental training before assignment | No currently qualified PIP is available without reassigning from an equally-scored campaign |
4. Portfolio matrix
| Campaign / site | Risk tier score | Batch value score | Regulatory proximity score | Site maturity score | Qualification match score | Composite score | Rank | Coverage decision | Rationale | Decision owner | Date |
|---|---|---|---|---|---|---|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: on-site / hybrid / virtual / none>> | <<FILL>> | <<FILL>> | <<FILL>> |
Add one row per campaign. Sort by composite score, highest first, and draw the coverage line at the point where available capacity actually runs out, not at a round number chosen in advance.
5. Below-the-line campaigns
Every campaign that scores below the coverage line still gets a row and a documented decision, never a silent omission.
| Campaign / site | Composite score | Coverage assigned instead | Rationale | Accepted by | Date |
|---|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL: virtual oversight, reduced-frequency spot checks, none>> | <<FILL>> | <<FILL: named Quality Assurance approver for any genuine coverage gap>> | <<FILL>> |
A below-the-line campaign that itself scores in the top risk tier on the single-campaign table (a first campaign at a new site, a non-recoverable batch) needs an explicit, named Quality Assurance sign-off before its coverage is reduced, not just a program-lead note.
6. Recurring capacity shortfall trigger
| Field | Entry |
|---|---|
Has a risk-tier-one campaign been cut below the coverage line in each of the last <<FILL: e.g. 3>> consecutive periods? | <<FILL: Yes/No>> |
| If yes, this is a staffing gap, not a prioritization exercise | <<FILL: escalation raised to, e.g. sponsor technical operations leadership, with the recurring-cut evidence attached>> |
7. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
8. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (PIP Program Lead) | <<FILL>> | ||
| Reviewer (Sponsor Quality Leadership) | <<FILL>> |
Filled specimen
Extract for Acme Therapeutics’ Q3 2026 portfolio: six concurrent campaigns across four CDMOs, three qualified PIPs available. Company and CDMO names are illustrative.
| Campaign / site | Risk tier | Batch value | Regulatory proximity | Site maturity | Qualification match | Composite | Rank | Coverage decision | Rationale |
|---|---|---|---|---|---|---|---|---|---|
| ATX-CAR7 first campaign, Meridian Fill Services | 5 | 5 | 3 | 5 | 5 | 23 | 1 | On-site, full campaign | First campaign at a new site, autologous product, no performance history |
| ATX-AAV9 fill, CryoVector CDMO | 4 | 4 | 5 | 3 | 4 | 20 | 2 | On-site, critical steps only | PAI-relevant filing references this campaign directly within two quarters |
| ATX-101 mAb, routine batch 14, Acme’s tenth-campaign partner | 1 | 2 | 1 | 1 | 5 | 10 | 4 | Virtual, spot check | Mature relationship, clean trend, qualified PIP available but low marginal value |
| ATX-410 lyophilized biologic, post-483 recovery campaign | 5 | 3 | 4 | 3 | 2 | 17 | 3 | On-site, elevated cadence | Post-483 recovery per the risk table; qualification gap being closed this period |
| ATX-207 oligonucleotide fill, new CDMO onboarding | 4 | 2 | 2 | 5 | 1 | 14 | 5 | Below the line: virtual, no on-site PIP available | No qualified PIP without pulling from a higher-ranked campaign; accepted risk on file |
| ATX-055 mAb, routine batch 22, same tenth-campaign partner | 1 | 2 | 1 | 1 | 3 | 8 | 6 | Below the line: no dedicated coverage | Lowest composite score in the portfolio; covered by the site’s own clean trend and periodic spot checks under a separate campaign |
Below-the-line detail for ATX-207: composite score 14, virtual oversight assigned instead of on-site, rationale “new CDMO onboarding scores high on site maturity risk, but no PIP qualified for this product is available this period without pulling capacity from ATX-CAR7 or ATX-AAV9, both scoring higher; risk accepted for one campaign pending the next qualification cohort,” accepted by Acme’s VP Quality, dated 2026-07-02.
Recurring shortfall trigger: ATX-207-class new-onboarding campaigns have now been cut below the line in two of the last three quarters. Not yet at the three-quarter trigger, but flagged in section 6 for tracking into Q4.
Common inspection findings this matrix prevents
- Oversight capacity allocated across concurrent campaigns with no documented risk basis, discovered when an inspector asks why one risk-flagged campaign got a PIP and a similar one at another site did not.
- A below-the-line coverage reduction on a genuinely high-risk campaign with no named Quality Assurance acceptance on file.
- A recurring capacity shortfall handled as a one-time prioritization exercise every quarter instead of surfaced as a staffing gap needing a headcount decision.
- A portfolio decision that exists only in a program manager’s calendar or memory, with no matrix a reviewer can check against the single-campaign risk criteria.
How to adapt this matrix
- Set the period, available PIP capacity, and named qualified individuals in the header and section 2 before scoring anything.
- Score every campaign meeting the single-campaign risk criteria, not just the ones that feel urgent; an unscored campaign cannot be ranked.
- Draw the coverage line where capacity genuinely runs out, and route every below-the-line high-risk campaign through a named Quality Assurance acceptance, not a program-lead note.
- Track the recurring-shortfall trigger in section 6 every period; three consecutive cuts to risk-tier-one campaigns is a staffing conversation, not a scoring problem.
- Re-run this matrix on a fixed cadence tied to the portfolio’s actual campaign turnover, not only when a shortfall is already visible.